Palmaz-Schatz
Generated by GPT-5-miniExpansion Funnel Raw 46 → Dedup 0 → NER 0 → Enqueued 0
| Palmaz-Schatz | |
|---|---|
| Name | Palmaz-Schatz |
| Occupation | Medical device |
| Known for | Balloon-expandable vascular stent |
| Invented | 1980s |
| Inventor | Julio Palmaz, Richard Schatz |
Palmaz-Schatz.
Palmaz-Schatz denotes the balloon-expandable vascular stent developed in the 1980s by Julio C. Palmaz and Richard L. Schatz, and commercialised by Johnson & Johnson subsidiaries after licensing and collaboration with Cordis Corporation and Advanced Cardiovascular Systems. The device transformed percutaneous treatment of coronary artery disease, influenced interventional practice at institutions such as Cleveland Clinic and Mayo Clinic, and prompted regulatory review by agencies including the United States Food and Drug Administration and the European Medicines Agency. Its development intersected with contemporaneous innovations from inventors like Andreas Gruentzig and companies such as Boston Scientific and Medtronic.
Background and development
Development began after Julio C. Palmaz filed initial patents for a tubular, slotted, metal scaffold to scaffold stenotic vessels, inspired by balloon angioplasty techniques pioneered by Andreas Gruentzig at University Hospital of Zurich. Co-inventor Richard L. Schatz contributed to bench testing and early clinical translation performed at centres including St. Luke's Hospital and Mount Sinai Hospital. Early prototypes were evaluated in animal labs such as Wyeth Research facilities and in preclinical studies at Massachusetts General Hospital, informing iterations in strut geometry and deployment strategy. Collaboration with industrial partners, notably Cordis Corporation and later Johnson & Johnson, enabled scaling manufacturing processes and conducting multicentre trials like those overseen by principal investigators affiliated with Harvard Medical School and Stanford University Medical Center.
Device design and materials
The Palmaz-Schatz design used slotted tube architecture machined from stainless steel alloys such as 316L, with later variants exploring cobalt-chromium alloys used by competitors like Boston Scientific. The stent was mounted on angioplasty balloons produced by companies such as Advanced Cardiovascular Systems and delivered via catheters developed alongside industry suppliers including Abbott Laboratories. Design features included longitudinal slots, circumferential crowns, and flared ends to reduce edge restenosis, with production tolerances influenced by standards from organisations like American Society for Testing and Materials and manufacturing partners like Siemens. Surface treatments and later drug-eluting coatings from collaborations with firms such as Boston Scientific and Medtronic were incorporated in successor devices to address neointimal hyperplasia observed in clinical follow-up.
Clinical use and indications
Clinicians used the Palmaz-Schatz stent for percutaneous coronary interventions to treat focal atherosclerotic lesions in patients referred from cardiac centres like Cleveland Clinic and Mayo Clinic. Indications mirrored guidance from professional societies such as the American College of Cardiology and European Society of Cardiology for management of acute coronary syndrome, restenotic lesions, and saphenous vein graft stenosis. Trials compared stented angioplasty to balloon angioplasty pioneered by Andreas Gruentzig and to surgical revascularisation options like coronary artery bypass grafting performed by surgeons trained at institutions such as Johns Hopkins Hospital. Operators used imaging adjuncts such as intravascular ultrasound and fluoroscopy systems from vendors like GE Healthcare and Philips during deployment.
Outcomes and complications
Early multicentre registries and randomised trials reported reductions in acute elastic recoil and abrupt vessel closure compared with balloon angioplasty, influencing outcomes documented in journals affiliated with American Heart Association and European Society of Cardiology. However, the device was associated with in-stent restenosis due to neointimal hyperplasia, thrombosis prompting antiplatelet strategies involving drugs from Bristol-Myers Squibb and AstraZeneca, and edge complications managed at centres including Mount Sinai Hospital. Long-term surveillance by agencies such as the United States Food and Drug Administration and clinical networks at Duke University Medical Center informed practice changes, leading to adoption of dual antiplatelet therapy protocols recommended by professional bodies like Society for Cardiovascular Angiography and Interventions.
Regulatory approval and commercialisation
Regulatory pathways involved premarket submissions to the United States Food and Drug Administration and conformity assessment for the CE marking in the European Union. Commercialisation was driven by licensing agreements with Cordis Corporation and corporate activities of Johnson & Johnson, which invested in manufacturing capacity and distribution networks spanning markets served by distributors such as Cardinal Health. Marketing efforts targeted interventional cardiologists at meetings like the American College of Cardiology Annual Scientific Session and Transcatheter Cardiovascular Therapeutics conference. Post-market surveillance and product iterations responded to feedback from hospitals including Cleveland Clinic and academic trial networks coordinated through institutions such as Harvard Medical School.
Legal and patent disputes
The Palmaz-Schatz intellectual property portfolio prompted litigation and licensing negotiations involving parties like Cordis Corporation, Johnson & Johnson, and other device makers including Boston Scientific and Medtronic. Patent enforcement actions appeared before courts such as the United States Court of Appeals for the Federal Circuit and in arbitration panels involving international firms operating in markets governed by laws of jurisdictions including Germany and United Kingdom. Settlements and licensing agreements influenced technology transfer to companies like Abbott Laboratories and shaped standard-setting discussions at organisations such as the International Organization for Standardization.